[FOLFOX方案用于不可切除的晚期或复发性结直肠癌患者的临床应用]

[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].

作者信息

Minami Kazuhito, Kameda Akira, Tsutani Yasuhiro, Suzuki Takahisa, Miyahara Eiji, Noso Yoshihiro

机构信息

Dept. of Surgery, Saiseikai Hiroshima Hospital.

出版信息

Gan To Kagaku Ryoho. 2007 Apr;34(4):573-7.

PMID:17431362

Abstract

FOLFOX regimens were administered to 14 patients with unresectable advanced or recurrent colorectal cancer from 1 to 9 cycles (median 5 cycles). In our patient characteristics, 10 patients had previous chemotherapies, 3 patients showed performance status 3. The response rate was 21%, and median time to progression was 5.0 months. Frequency of grade 3/4 adverse effect was 57% in neutropenia, 36% in leucopenia, 36% in thrombocytopenia, and 7% in allergic reaction. Only 64% patients could complete the treatment, for these adverse events brought treatment failure at 3-6 cycles. Median relative dose-intensity was 80-90% during 1-4 cycles, but about 50% after 5 cycles for these adverse events. No patient had grade 3 neurologic toxicity,because no one was administered over 10 cycles. FOLFOX regimens showed good anti-tumor effects but poor tolerability after 5-6 cycles in our patients.

摘要

对14例无法切除的晚期或复发性结直肠癌患者给予FOLFOX方案治疗，疗程为1至9个周期（中位周期数为5个周期）。在我们的患者特征中，10例患者曾接受过化疗，3例患者的体能状态为3级。缓解率为21%，中位疾病进展时间为5.0个月。3/4级不良反应的发生率在中性粒细胞减少症中为57%，白细胞减少症中为36%，血小板减少症中为36%，过敏反应中为7%。仅64%的患者能够完成治疗，因为这些不良事件导致3至6个周期的治疗失败。在1至4个周期中，中位相对剂量强度为80%至90%，但在5个周期后，由于这些不良事件，该数值约为50%。没有患者出现3级神经毒性，因为没有患者接受超过10个周期的治疗。在我们的患者中，FOLFOX方案在5至6个周期后显示出良好的抗肿瘤效果，但耐受性较差。